Back to results
US 10,357,556 B2Granted
Methods and compositions for T cell generation and uses thereof
AssigneeWashington University
InventorsHerbert W. Virgin, IV, Hiutung Chu, Sarkis K. Mazmanian
Life of this patent
Estimating the term…
Abstract
Among the various aspects of the present disclosure is the provision of a method of treating an inflammatory bowel disease. Another aspect provides the provision of a screening method for therapeutic agents. Another aspect provides a method of detecting Treg cells to determine if a subject has an inflammatory disease. The present disclosure provides for methods of treatment, diagnosis, and screening for drugs for colitis and ileitis.
Claims14
A method of screening a test compound, comprising:
- (a) incubating a wild type dendritic cell, an autophagy-related (Atg) gene-mutant dendritic cell, a wild type macrophage, or an Atg gene-mutant macrophage with regulatory T cell (Treg) precursors in the presence of at least one test compound or salt thereof;
- (b) detecting a level of Treg cells generated or detecting a level of cytokine secretions;
- and
- (c) (i) comparing the level of Treg cells generated or cytokine secretions in the Atg gene-mutant dendritic cell in the presence of a test compound to the level of Treg cells generated or cytokine secretions in the in the Atg gene-mutant dendritic cell in the absence of the test compound or (ii) comparing the level of Treg cells generated or cytokine secretions in the Atg gene-mutant dendritic cell in the presence of a test compound to the level of Treg cells generated or cytokine secretions in the in the Atg wild-type dendritic cell in the presence of the test compound;
- or
- (d) (i) comparing the level of Treg cells generated or cytokine secretions in the Atg gene-mutant macrophage in the presence of a test compound with the level of Treg cells generated or cytokine secretions in the Atg gene-mutant macrophage in the absence of the test compound or (ii) comparing the level of Treg cells generated or cytokine secretions in the Atg gene-mutant macrophage in the presence of a test compound to the level of Treg cells generated or cytokine secretions in the in the Atg wild-type macrophage in the presence of the test compound;
- and
- (e) determining if the test compound restores Treg generation;
- wherein the test compound may or may not restore Treg generation.
6 more elements
A method of screening a test compound, comprising:
- (a) obtaining one or more proteins associated with Treg generation;
- (b) incubating the proteins associated with Treg generation in the presence or absence of at least one test compound or salt thereof;
- (c) detecting a ligand-protein interaction;
- (d) comparing the ligand-protein interaction of the protein in the presence of at least one test compound to the ligand-protein interaction of the protein in the absence of at least one test compound;
- and
- (e) determining if the test compound restores Treg generation;
- wherein,
- the test compound may or may not restore Treg generation;
- and
- the test compound targets a protein selected from one or more of the group consisting of:
- RUBICON, ATG16L1, ATG16L1T300A, ATG7, and ATG5.
8 more elements
Dependencies are inferred from the claim text.